{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T01:11:21Z","timestamp":1780881081717,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,22]],"date-time":"2014-11-22T00:00:00Z","timestamp":1416614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2415-14-138","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T21:01:55Z","timestamp":1416603715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain"],"prefix":"10.1186","volume":"14","author":[{"given":"Rosa M","family":"Coco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Rosa","family":"Sanabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Castrejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Isabel","family":"Lopez-Galvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Monje-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fernandez-Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"de Juan-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Villaron-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,22]]},"reference":[{"key":"500_CR1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","volume":"291","author":"NM Bressler","year":"2004","unstructured":"Bressler NM: Age-related macular degeneration is the leading cause of blindness. JAMA. 2004, 291: 1900-1901. 10.1001\/jama.291.15.1900.","journal-title":"JAMA"},{"key":"500_CR2","doi-asserted-by":"publisher","first-page":"830837","DOI":"10.1155\/2013\/830837","volume":"2013","author":"M Hanout","year":"2013","unstructured":"Hanout M, Ferraz D, Ansari M, Maqsood N, Kherani S, Sepah YJ, Rajagopalan N, Ibrahim M, Do DV, Nguyen QD: Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development. BioMed Res Int. 2013, 2013: 830837-doi:10.1155\/2013\/830837","journal-title":"BioMed Res Int"},{"key":"500_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000319906","volume":"225","author":"J Mones","year":"2011","unstructured":"Mones J: A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice. Ophthalmologica. 2011, 225: 112-119. 10.1159\/000319906.","journal-title":"Ophthalmologica"},{"key":"500_CR4","volume-title":"Gu\u00edas de Pr\u00e1ctica Cl\u00ednica de la SERV. Guia para el tratamiento de la Degeneraci\u00f3n Macular Asociada a la Edad (DMAE) exudativa","author":"JM Ruiz-Moreno","year":"2009","unstructured":"Ruiz-Moreno JM: Gu\u00edas de Pr\u00e1ctica Cl\u00ednica de la SERV. Guia para el tratamiento de la Degeneraci\u00f3n Macular Asociada a la Edad (DMAE) exudativa. 2009, \n                    https:\/\/www.serv.es\/html\/documentos-serv.php\n                    \n                   Accessed 17 Apr 2014"},{"key":"500_CR5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","volume":"97","author":"FG Holz","year":"2013","unstructured":"Holz FG, Bandello F, Gillies M, Mitchell P, Osborne A, Sheidow T, Souied E, Figueroa MS, LUMINOUS Steering Committee: Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013, 97: 1161-1167. 10.1136\/bjophthalmol-2013-303232.","journal-title":"Br J Ophthalmol"},{"key":"500_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","volume":"33","author":"SY Cohen","year":"2013","unstructured":"Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Quer\u00e9 S, Schneider V, LUMIERE Study Group: Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina. 2013, 33: 474-481. 10.1097\/IAE.0b013e31827b6324.","journal-title":"Retina"},{"key":"500_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1755-3768.2012.02493.x","volume":"91","author":"RP Finger","year":"2013","unstructured":"Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG: Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol. 2013, 91: 540-546. 10.1111\/j.1755-3768.2012.02493.x.","journal-title":"Acta Ophthalmol"},{"key":"500_CR8","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.ophtha.2013.05.018","volume":"120","author":"A Rasmussen","year":"2013","unstructured":"Rasmussen A, Bloch SB, Fuchs J, Hansen LH, Larsen M, Lacour M, Lund-Andersen H, Sander B: A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2013, 120: 2630-2636. 10.1016\/j.ophtha.2013.05.018.","journal-title":"Ophthalmology"},{"key":"500_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ophtha.2006.07.017","volume":"114","author":"JJ Wang","year":"2007","unstructured":"Wang JJ, Rochtchina E, Lee AJ, Chia EM, Smith W, Cumming RG, Mitchell P: Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology. 2007, 114: 92-98. 10.1016\/j.ophtha.2006.07.017.","journal-title":"Ophthalmology"},{"key":"500_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","volume":"121","author":"E Daniel","year":"2013","unstructured":"Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG, for the Comparison of Age-related Macular Degeneration Treatments Trials Research Group: Risk of scar in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2013, 121: 656-666.","journal-title":"Ophthalmology"},{"key":"500_CR11","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","volume":"119","author":"MA Singer","year":"2012","unstructured":"Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, Tuomi L: HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012, 119: 1175-1183. 10.1016\/j.ophtha.2011.12.016.","journal-title":"Ophthalmology"},{"key":"500_CR12","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, for the SEVEN-UP Study Group: Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON A Multicenter Cohort Study (SEVEN-UP). Ophthalmology. 2013, 120: 2292-2299. 10.1016\/j.ophtha.2013.03.046.","journal-title":"Ophthalmology"},{"key":"500_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bjo.2009.159160","volume":"94","author":"P Mitchell","year":"2010","unstructured":"Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Pruente C, Schmidt-Erfurth UM, Tano Y, Wolf S: Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010, 94: 2-13. 10.1136\/bjo.2009.159160.","journal-title":"Br J Ophthalmol"},{"key":"500_CR14","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/IAE.0b013e318207d152","volume":"31","author":"L Arias","year":"2011","unstructured":"Arias L, Roman I, Masuet-Aumatell C, Rubio MJ, Caminal JM, Catala J, Pujol O: One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. Retina. 2011, 31: 1261-1267. 10.1097\/IAE.0b013e318207d152.","journal-title":"Retina"},{"key":"500_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0039-6257(05)80092-X","volume":"39","author":"AC Bird","year":"1995","unstructured":"Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R: The International ARM Epidemiological Study Group: An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol. 1995, 39: 367-374. 10.1016\/S0039-6257(05)80092-X.","journal-title":"Surv Ophthalmol"},{"key":"500_CR16","volume-title":"A Language and Environment for Statistical Computing","author":"Core Team R","year":"2013","unstructured":"Core Team R: A Language and Environment for Statistical Computing. 2013, Vienna, Austria: R Foundation for Statistical Computing, URL \n                    http:\/\/www.R-project.org\/\n                    \n                   2013"},{"key":"500_CR17","volume-title":"lme4: Linear mixed-effects models using Eigen and S4. R package version 1.1-6","author":"D Bates","year":"2013","unstructured":"Bates D, Maechler M, Bolker B, Walker S: lme4: Linear mixed-effects models using Eigen and S4. R package version 1.1-6. 2013, \n                    http:\/\/cran.r-project.org\/web\/packages\/lme4\/index.html\n                    \n                   2013 Accessed 17 Apr 2014"},{"key":"500_CR18","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","volume":"144","author":"PK Kaiser","year":"2007","unstructured":"Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR: Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007, 144: 850-857. 10.1016\/j.ajo.2007.08.012.","journal-title":"Am J Ophthalmol"},{"key":"500_CR19","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/archopht.125.11.1460","volume":"125","author":"TS Chang","year":"2007","unstructured":"Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, MARINA Study Group: Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007, 125: 1460-1469. 10.1001\/archopht.125.11.1460.","journal-title":"Arch Ophthalmol"},{"key":"500_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"AE Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007, 143: 566-583. 10.1016\/j.ajo.2007.01.028.","journal-title":"Am J Ophthalmol"},{"key":"500_CR21","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ajo.2011.09.013","volume":"153","author":"JH Lim","year":"2012","unstructured":"Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD, Hageman G, Guymer RH: Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol. 2012, 153: 678-686. 10.1016\/j.ajo.2011.09.013.","journal-title":"Am J Ophthalmol"},{"key":"500_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1097\/IAE.0b013e3182831265","volume":"33","author":"N Toalster","year":"2013","unstructured":"Toalster N, Russell M, Ng P: A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina. 2013, 33: 1351-1358. 10.1097\/IAE.0b013e3182831265.","journal-title":"Retina"},{"key":"500_CR23","volume-title":"Graefes Arch Clin Exp Ophthalmol","author":"M Hata","year":"2014","unstructured":"Hata M, Tsujikawa A, Miyake M, Yamashiro K, Ooto S, Oishi A, Nakanishi H, Takahashi A, Yoshimura N: Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2014, Epub ahead of print"},{"key":"500_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/IAE.0b013e3181de5609","volume":"31","author":"H Oubraham","year":"2011","unstructured":"Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, Fajnkuchen F, Tadayoni R: Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina. 2011, 31: 26-30. 10.1097\/IAE.0b013e3181de5609.","journal-title":"Retina"},{"key":"500_CR25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, SUSTAIN Study Group: Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011, 118: 663-671. 10.1016\/j.ophtha.2010.12.019.","journal-title":"Ophthalmology"},{"key":"500_CR26","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1167\/iovs.08-1877","volume":"49","author":"S Liakopoulos","year":"2008","unstructured":"Liakopoulos S, Ongchin S, Bansal A, Msutta S, Walsh AC, Updike PG, Sadda SR: Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008, 49: 5048-5054. 10.1167\/iovs.08-1877.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"500_CR27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3129\/i10-082","volume":"45","author":"T Bandukwala","year":"2010","unstructured":"Bandukwala T, Muni RH, Schwartz C, Eng KT, Kertes PJ: Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review. Can J Ophthalmol. 2010, 45: 590-595. 10.3129\/i10-082.","journal-title":"Can J Ophthalmol"},{"key":"500_CR28","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2009.05.033","volume":"116","author":"H Dadgostar","year":"2009","unstructured":"Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK: Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology. 2009, 116: 1740-1747. 10.1016\/j.ophtha.2009.05.033.","journal-title":"Ophthalmology"},{"key":"500_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/bjophthalmol-2013-303444","volume":"98","author":"K Hatz","year":"2014","unstructured":"Hatz K, Pr\u00fcnte C: Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol. 2014, 98: 188-194.","journal-title":"Br J Ophthalmol"},{"key":"500_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00417-001-0378-2","volume":"240","author":"J Bermig","year":"2002","unstructured":"Bermig J, Tylla H, Jochmann C, Nestler A, Wolf S: Angiographic findings in patients with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2002, 240: 169-175. 10.1007\/s00417-001-0378-2.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"500_CR31","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1167\/iovs.09-3610","volume":"50","author":"P Malamos","year":"2009","unstructured":"Malamos P, Sacu S, Georgopoulos M, Kiss C, Pruente C, Schmidt-Erfurth U: Correlation of high-definition optical coherence tomography and fluorescein angiography imaging in neovascular macular degeneration. Invest Ophthalmol Vis Sci. 2009, 50: 4926-4933. 10.1167\/iovs.09-3610.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"500_CR32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ophtha.2003.05.030","volume":"111","author":"TW Olsen","year":"2004","unstructured":"Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer ER: Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology. 2004, 111: 250-255. 10.1016\/j.ophtha.2003.05.030.","journal-title":"Ophthalmology"},{"key":"500_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ophtha.2012.07.026","volume":"120","author":"R Silva","year":"2013","unstructured":"Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, Seres A, Gekkieva M, Nieweg A, Pilz S, SECURE Study Group: The SECURE study long-term safety of ranibizumab 0.5\u00a0mg in neovascular age-related macular degeneration. Ophthalmology. 2013, 120: 130-139. 10.1016\/j.ophtha.2012.07.026.","journal-title":"Ophthalmology"},{"key":"500_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.exer.2004.09.015","volume":"80","author":"RE Neal","year":"2005","unstructured":"Neal RE, Bettelheim FA, Lin C, Winn KC, Garland DL, Zigler JS: Alterations in human vitreous humour following cataract extraction. Exp Eye Res. 2005, 80: 337-347. 10.1016\/j.exer.2004.09.015.","journal-title":"Exp Eye Res"},{"key":"500_CR35","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.ophtha.2012.11.042","volume":"120","author":"DV Weinberg","year":"2013","unstructured":"Weinberg DV, Shapiro H, Ehrlich JS: Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology. 2013, 120: 1278-1282. 10.1016\/j.ophtha.2012.11.042.","journal-title":"Ophthalmology"},{"key":"500_CR36","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/0016-5085(94)90047-7","volume":"106","author":"EJ Kuipers","year":"1994","unstructured":"Kuipers EJ, Pe\u00f1a AS, Meuwissen SG: H. pylori and gastric cancer: limitations of retrospective studies. Gastroenterology. 1994, 106: 1398-1400.","journal-title":"Gastroenterology"},{"key":"500_CR37","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1097\/IAE.0b013e318240a516","volume":"32","author":"SY Cohen","year":"2012","unstructured":"Cohen SY, Oubraham H, Uzzan J, Dubois L, Tadayoni R: Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings. Retina. 2012, 32: 1480-1485. 10.1097\/IAE.0b013e318240a516.","journal-title":"Retina"},{"key":"500_CR38","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ: Novel method for analyzing Snellen visual acuity measurements. Retina. 2010, 30: 1046-1050. 10.1097\/IAE.0b013e3181d87e04.","journal-title":"Retina"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-14-138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2415-14-138\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-14-138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-14-138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T22:19:05Z","timestamp":1548195545000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/1471-2415-14-138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,22]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["500"],"URL":"https:\/\/doi.org\/10.1186\/1471-2415-14-138","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,22]]},"assertion":[{"value":"22 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"138"}}